Authors:
Hayes, DF
Yamauchi, H
Broadwater, G
Cirrincione, CT
Rodrigue, SP
Berry, DA
Younger, J
Panasci, LL
Millard, F
Duggan, DB
Norton, L
Henderson, IC
Citation: Df. Hayes et al., Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and leukemia group B study 8662, CLIN CANC R, 7(9), 2001, pp. 2703-2711
Authors:
Harris, LN
Liotcheva, V
Broadwater, G
Ramirez, MJ
Maimonis, P
Anderson, S
Everett, T
Harpole, D
Moore, MB
Berry, DA
Rizzeri, D
Vredenburgh, JJ
Bentley, RC
Citation: Ln. Harris et al., Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy, J CL ONCOL, 19(6), 2001, pp. 1698-1706
Authors:
Lewis, RJ
Berry, DA
Cryer, H
Fost, N
Krome, R
Washington, GR
Houghton, J
Blue, JW
Bechhofer, R
Cook, T
Fisher, M
Citation: Rj. Lewis et al., Monitoring a clinical trial conducted under the food and drug administration regulations allowing a waiver of prospective informed consent: The diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial, ANN EMERG M, 38(4), 2001, pp. 397-404
Authors:
Kupfer, DJ
Baltimore, RS
Berry, DA
Breslau, N
Ellinwood, EH
Ferre, J
Ferriero, DM
Fuchs, LS
Guze, SB
Hamburg, BA
McGlothlin, J
Turner, SM
Vonnegut, M
Abikoff, H
Anderson, S
Arnold, LE
Barkley, RA
Biederman, J
Bird, HR
Breggin, PR
Carey, WB
Chemers, B
Conners, CK
Cooper, JR
Danielson, L
Feussner, G
Forness, SR
Greenhill, LL
Hinshaw, SP
Hoagwood, K
Jensen, PS
Johnston, C
Kalivas, PW
Kelleher, KJ
Klein, RG
Lahey, BB
Lambert, NM
Loney, J
Pelham, WE
Rowland, AS
Swanson, J
Tannock, R
Wilens, TE
Wolraich, ML
Citation: Dj. Kupfer et al., National Institutes of Health Consensus Development Conference Statement: Diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD), J AM A CHIL, 39(2), 2000, pp. 182-193
Authors:
Berry, DA
Muss, HB
Thor, AD
Dressler, L
Liu, ET
Broadwater, G
Budman, DR
Henderson, IC
Barcos, M
Hayes, D
Norton, L
Citation: Da. Berry et al., HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer, J CL ONCOL, 18(20), 2000, pp. 3471-3479
Authors:
Berry, DA
Balcar, VJ
Barden, JA
Keogh, A
dos Remedios, CG
Citation: Da. Berry et al., Determination of P2X(1)alpha-sarcoglycan (adhalin) expression levels in failing human dilated cardiomyopathic left ventricles, ELECTROPHOR, 21(17), 2000, pp. 3857-3862
Authors:
Brooks, PJ
Wise, DS
Berry, DA
Kosmoski, JV
Smerdon, MJ
Somers, RL
Mackie, H
Spoonde, AY
Ackerman, EJ
Coleman, K
Tarone, RE
Robbins, JH
Citation: Pj. Brooks et al., The oxidative DNA lesion 8,5 '-(S)-cyclo-2 '-deoxyadenosine is repaired bythe nucleotide excision repair pathway and blocks gene expression in mammalian cells, J BIOL CHEM, 275(29), 2000, pp. 22355-22362
Citation: Da. Berry et Ad. Thor, erbB-2, p53, and efficacy of adjuvant therapy in lymph node positive breast cancer - Response, J NAT CANC, 91(8), 1999, pp. 728-729
Citation: Da. Berry, Benefits and risks of screening mammography for women in their forties: a statistical appraisal - Response, J NAT CANC, 91(4), 1999, pp. 383-384
Citation: Da. Berry et Dr. Budman, Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer - Response, J NAT CANC, 91(3), 1999, pp. 286-287
Citation: Da. Berry et Dr. Budman, Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer - Response, J NAT CANC, 91(16), 1999, pp. 1425-1425
Authors:
Costanza, ME
Weiss, RB
Henderson, IC
Norton, L
Berry, DA
Cirrincione, C
Winer, E
Wood, WC
Frei, E
McIntyre, OR
Schilsky, RL
Citation: Me. Costanza et al., Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: Report of a randomized study - Cancer and leukemia group B 8642, J CL ONCOL, 17(5), 1999, pp. 1397-1406
Authors:
Parmigiani, G
Berry, DA
Winer, EP
Tebaldi, C
Iglehart, JD
Prosnitz, LR
Citation: G. Parmigiani et al., Is axillary lymph node dissection indicated for early-stage breast cancer?A decision analysis, J CL ONCOL, 17(5), 1999, pp. 1465-1473
Authors:
Bluman, LG
Rimer, BK
Berry, DA
Borstelmann, N
Iglehart, JD
Regan, K
Schildkraut, J
Winer, EP
Citation: Lg. Bluman et al., Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2, J CL ONCOL, 17(3), 1999, pp. 1040-1046
Authors:
Abrams, J
Aisner, J
Cirrincione, C
Berry, DA
Muss, HB
Cooper, MR
Henderson, IC
Panasci, L
Kirshner, J
Ellerton, J
Norton, L
Citation: J. Abrams et al., Dose-response trial of megestrol acetate in advanced breast cancer: Cancerand leukemia group B phase III study 8741, J CL ONCOL, 17(1), 1999, pp. 64-73